As BMS-paired triplet misses survival mark in kidney cancer, Exelixis shifts focus elsewhere
While Exelixis has abandoned a plan to seek an FDA approval for a combination of its Cabometyx and Bristol Myers' Opdivo and Yervoy in kidney cancer, the biotech is hopeful that its next-gen tyrosine kinase inhibitor could have a place in the competitive field.
While Exelixis has abandoned a plan to seek an FDA approval for a combination of its Cabometyx and Bristol Myers' Opdivo and Yervoy in kidney cancer, the biotech is hopeful that its next-gen tyrosine kinase inhibitor could have a place in the competitive field.
